QR Code

Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Wiley 2020-07-01
Rangatū:Endocrinology, Diabetes & Metabolism
Ngā marau:
albuminuria
CCR2
diabetes
kidney
MCP‐1
propagermanium
Urunga tuihono:https://doi.org/10.1002/edm2.159
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite